Herantis Pharma Plc provides update on non-invasive next generation CDNF (xCDNF) development
Herantis Pharma PlcCompany release, insider information 30 December 2019 at 11:00 AM Eastern European TimeHerantis Pharma Plc (“Herantis” or “Company”) announced today an update on the development of its non-invasive next generation CDNF, or xCDNF. The xCDNF development program was initiated in July 2018 to develop cell-protecting molecules that penetrate the blood-brain barrier, building on the Company’s cumulated expertise on CDNF, Herantis’ lead compound in Parkinson disease. The xCDNF program is based on the discovery of certain CDNF-derived peptides penetrating the blood-brain